Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...

Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)Findings in ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the ...

A research team led by Prof. Sun Cheng from the University of Science and Technology of China (USTC), in collaboration with ...

Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most aggressive malignancies. In a recent study published in Nature Communications, ...

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...